References
- Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa/2020. Incidência de Câncer no Brasil; 2019. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf
- Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. 2014;106(5):dju055.
- Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125(3):627–636.
- Prado-Vazquez G, Gámez-Pozo A, Trilla-Fuertes L, et al. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses. Sci. Rep. 2019;9:1538.
- Krishnamurthy A, Jimeno A. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. Drugs Today. 2017;53(4):217–237.
- Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
- U.S. Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools); 2020. https://www.fda.gov/medical-devices/vitro-diagnostics/list-clearedor-approved-companion-diagnostic-devices-vitro-and-imaging-tools
- Genentech. TECENTRIQ (atezolizumab) - FDA. 1–53; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s027lbl.pdf
- Rugo HS, Loi S, Adams S, et al. Performance of PD-L1 immunohistochemistry assays in unresectable locally advanced or metastatic triple-negative breast cancer: post hoc analysis of IMpassion130. ESMO Congr. 2019;30(5):v858–v859.
- Instituto Brasileiro de Geografia e Estatística (IBGE). Medidas Antropométricas; 2013. Available from: https://www.ibge.gov.br/estatisticas/sociais/saude/9160-pesquisa-nacional-de-saude.html?=&t=resultados.
- Agência Nacional de Saúde Suplementar. RESOLUÇÃO NORMATIVA - RN No 428, DE 7 DE NOVEMBRO DE 2017; 2017. https://www.ans.gov.br/component/legislacao/?view=legislacao&task=TextoLei&format=raw&id=MzUwMg==
- Rugo H, Loi S, Adams S, et al. Abstract PD1-07: exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: a retrospective substudy of IMpassion130. Cancer Res. 2020;80:PD1-07.
- Celgene Brasil Produtos Farmacêuticos Ltda. Abraxane. 1–23; 2020. http://www.anvisa.gov.br/datavisa/fila_bula/index.asp
- Agência Nacional de Saúde Suplementar (ANS). Correlação TUSS x ROL 2018; 2018.
- Câmara de Regulação do Mercado de Medicamentos (CMED). Lista de preços de medicamentos - preços fábrica e máximos ao consumidor; 2020. http://portal.anvisa.gov.br/listas-de-precos
- Associação Médica Brasileira (AMB). Classificação Brasileira Hierarquizada de Procedimentos Médico (CBHPM); 2018.
- Produtos Roche Químicos e Farmacêuticos S.A. Tecentriq (bula); 2020. http://www.anvisa.gov.br/datavisa/fila_bula/index.asp